Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients.

Intensive Care Med Exp · 2023 · PMC10423708 · PMID 37574520

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase 2a randomized controlled trial, nangibotide showed a trend toward a clinical benefit in septic shock patients, especially those presented with an activated TREM-1 pathway (i.e., high concentrations of plasma sTREM-1) [ 14 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.